Editorial: gluten-free but not pain-free in IBS-authors' reply

Affiliations

¹ Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
² Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
³ Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Editorial

Joost P Algera et al. Aliment Pharmacol Ther. 2022 Dec.

. 2022 Dec;56(11-12):1623-1624.

doi: 10.1111/apt.17279.

¹ Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
² Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
³ Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

No abstract available

Comment on

Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome.
Algera JP, Magnusson MK, Öhman L, Störsrud S, Simrén M, Törnblom H. Algera JP, et al. Aliment Pharmacol Ther. 2022 Nov;56(9):1318-1327. doi: 10.1111/apt.17239. Epub 2022 Sep 29. Aliment Pharmacol Ther. 2022. PMID: 36173041 Free PMC article. Clinical Trial.
Editorial: gluten-free but not pain-free in IBS.
Fitzpatrick JA, Halmos EP. Fitzpatrick JA, et al. Aliment Pharmacol Ther. 2022 Dec;56(11-12):1621-1622. doi: 10.1111/apt.17253. Aliment Pharmacol Ther. 2022. PMID: 36352748 No abstract available.

1. Fitzpatrick JA, Halmos EP. Editorial: gluten free but not pain free in IBS. Aliment Pharmacol Ther. 2022; 56:1621-1622.
1. Algera JP, Magnusson MK, Öhman L, Störsrud S, Simrén M, Törnblom H. Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome. Aliment Pharmacol Ther. 2022;56:1318-1327.
1. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-407. https://doi.org/10.1053/j.gastro.2016.02.031
1. Törnblom H, Goosey R, Wiseman G, Baker S, Emmanuel A. Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: results from patient and healthcare professional surveys. United Eur Gastroenterol J. 2018;6(9):1417-27. https://doi.org/10.1177/2050640618787648
1. Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113-21. https://doi.org/10.1053/j.gastro.2016.08.003